STARGARDT DISEASE 1
Clinical trials for STARGARDT DISEASE 1 explained in plain language.
Never miss a new study
Get alerted when new STARGARDT DISEASE 1 trials appear
Sign up with your email to follow new studies for STARGARDT DISEASE 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy injection aims to slow vision loss in stargardt disease
Disease control Recruiting nowThis early-stage study tests a single injection of ACDN-01 into the eye for people with Stargardt disease or cone-rod dystrophy caused by ABCA4 gene mutations. The main goals are to check safety and find the best dose. About 15 adults with advanced vision loss will take part. The…
Matched conditions: STARGARDT DISEASE 1
Phase: PHASE1, PHASE2 • Sponsor: Ascidian Therapeutics, Inc • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New gene therapy aims to halt vision loss in rare eye disease
Disease control Recruiting nowThis early-stage trial tests a gene therapy called VG801 for people with Stargardt disease, an inherited condition that causes progressive vision loss. The study will enroll 15 participants aged 6 and older who have confirmed ABCA4 gene mutations and poor vision in one eye. The g…
Matched conditions: STARGARDT DISEASE 1
Phase: PHASE1, PHASE2 • Sponsor: VeonGen Therapeutics GmbH • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Eye screening study opens door to future treatments
Knowledge-focused Recruiting nowThis study is a pre-screening step for people with Stargardt disease or cone-rod dystrophy caused by ABCA4 gene mutations. It uses genetic tests and eye exams to see who may qualify for upcoming ACDN-01 clinical trials. About 50 participants will be enrolled to confirm their diag…
Matched conditions: STARGARDT DISEASE 1
Sponsor: Ascidian Therapeutics, Inc • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC